News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
News Pharma criticises 'heavy handed' NICE affordability test NHS England and NICE are attempting to reduce budget impact of drugs.
News NICE ‘pauses’ plans to introduce charges for pharma Plans by NICE to start charging pharma companies for appraising their medicines are to be ‘paused’ in order to allow the government to complete its life sciences strategy.
News Myeloma drugs Darzalex and Kyprolis rejected in Scotland SMC says "no" to Amgen and Janssen multiple myeloma drugs.
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
